Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a ...

New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network More than ...

Moderna (MRNA) stock is in focus as the company completes U.S. mRNA production network, investing $140M in Massachusetts and ...

Moderna is investing more than $140 million to bring drug manufacturing to its Massachusetts campus, a move that it says will ...

Moderna's $140 million investment in Norwood, Massachusetts, aims to complete its U.S. manufacturing loop, enhancing ...

The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

Cambridge, USA-based mRNA vaccines company Moderna today announced the expansion of its US manufacturing capabilities with ...

Mixed options sentiment in Moderna (MRNA), with shares down 94c near $23.98. Options volume relatively light with 49k contracts traded and calls ...

With the future of mRNA vaccines secure, an expert discusses the benefits of vaccine platform diversification.

Moderna will invest $140 million in expanding its U.S. manufacturing capacity and onshoring its drug manufacturing to its existing facility in Norwood, Mass. The company said it will now operate full ...

Three out of four adults in the United States live with conditions that can increase the risk of severe illness. 9 Chronic ...

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...